Izigulane ezinomhlaza wemiphunga, ngaba uvavanyo lwe-MRD luyimfuneko?

I-MRD (iSifo esiNcinci esiHlala phantsi), okanye iSifo esiNcinci esiHlala phantsi, linani elincinci leeseli zomhlaza (iiseli zomhlaza ezingaphenduliyo okanye ezingamelaniyo nonyango) ezihlala emzimbeni emva konyango lomhlaza.
I-MRD ingasetyenziswa njenge-biomarker, enesiphumo esihle esithetha ukuba izilonda eziseleyo zisenokufunyanwa emva konyango lomhlaza (kufunyenwe iiseli zomhlaza, kwaye iiseli zomhlaza eziseleyo zinokusebenza kwaye ziqale ukwanda emva konyango lomhlaza, nto leyo ekhokelela ekuphindeni kwesi sifo), ngelixa isiphumo esibi sithetha ukuba izilonda eziseleyo azifunyanwa emva konyango lomhlaza (akukho ziseli zomhlaza ezifunyenweyo);
Kuyaziwa ukuba uvavanyo lwe-MRD ludlala indima ebalulekileyo ekuchongeni izigulana zomhlaza wamaphaphu ezingezizo iiseli ezincinci (i-NSCLC) ezikwinqanaba lokuqala ezisengozini enkulu yokuphinda zibuye kwaye zikhokele unyango oluncedisayo emva kotyando olukhulu.
Imeko apho i-MRD ingasetyenziswa khona:

Kumhlaza wemiphunga osebenzayo kwinqanaba lokuqala

1. Emva kokususwa ngokupheleleyo kwezigulane ezinomhlaza wemiphunga ezingengoweeseli ezincinci kwinqanaba lokuqala, ukuba ne-MRD positive kubonisa umngcipheko ophezulu wokuphinda kuvele isifo kwaye kufuna ulawulo olusondeleyo. Ukubekwa esweni kwe-MRD kuyacetyiswa rhoqo kwiinyanga ezi-3-6;
2. Kucetyiswa ukuba kwenziwe uvavanyo lweklinikhi oluqhutywa emva kotyando lomhlaza wemiphunga ongengoweseli encinci ngokusekelwe kwi-MRD, kwaye kubonelelwe ngeendlela zonyango oluchanekileyo ngexesha lotyando kangangoko kunokwenzeka;
3. Cebisa ukuba kuhlolwe indima ye-MRD kuzo zombini iintlobo zezigulana, i-driver gene positive kunye ne-driver gene negative, ngokwahlukeneyo.

Umhlaza wemiphunga ongengoweeseli ezincinci ophucukileyo kwindawo ohlala kuyo

1. Uvavanyo lwe-MRD luyacetyiswa kwizigulana ezisele zikhululekile ngokupheleleyo emva kwe-radical chemoradiotherapy yomhlaza wemiphunga ongengoweseli encinci ophucukileyo, onokunceda ekumiseleni i-prognosis kunye nokwenza ezinye iindlela zonyango;
2. Kucetyiswa uvavanyo lwezonyango lonyango lokuqinisa olusekelwe kwi-MRD emva kwe-chemotherapy radiotherapy ukuze kubonelelwe ngeendlela zonyango lokuqinisa oluchanekileyo kangangoko kunokwenzeka.
Umhlaza wemiphunga ongengoweeseli ezincinci ophucukileyo
1. Kukho ukunqongophala kwezifundo ezifanelekileyo kwi-MRD kumhlaza wemiphunga ongengoweeseli ezincinci ophucukileyo;
2. Kucetyiswa ukuba i-MRD ifunyanwe kwizigulana ezisele zikhululekile ngokupheleleyo emva konyango olucwangcisiweyo lomhlaza wemiphunga ongengoweeseli ezincinci, nto leyo enokunceda ekugwebeni i-prognosis kunye nokwenza amanye amaqhinga okunyanga;
3. Kucetyiswa ukuba kwenziwe uphando malunga namaqhinga onyango olusekelwe kwi-MRD kwizigulane ezisele zikhululekile ngokupheleleyo ukuze kwandiswe ixesha lokukhululwa ngokupheleleyo kangangoko kunokwenzeka ukuze izigulane zikwazi ukufumana izibonelelo ezininzi.

Kuyabonakala ukuba ngenxa yokunqongophala kwezifundo ezifanelekileyo malunga nokufunyaniswa kwe-MRD kumhlaza wemiphunga ongengoweeseli ezincinci ophucukileyo, ukusetyenziswa kokufunyanwa kwe-MRD kunyango lwezigulane zomhlaza wemiphunga ongengoweeseli ezincinci ophucukileyo akukacaciswanga ngokucacileyo.
Kwiminyaka yakutshanje, inkqubela phambili kunyango olujoliswe kuyo kunye nonyango lwe-immunotherapy itshintshe indlela yonyango lwezigulane ezine-NSCLC ephucukileyo.
Ubungqina obuvelayo bubonisa ukuba ezinye izigulana ziphila ixesha elide kwaye kulindeleke ukuba zifumane ukuphumla ngokupheleleyo ngokuthatha imifanekiso. Ke ngoko, phantsi kwengcamango yokuba amanye amaqela ezigulana ezine-NSCLC ephucukileyo aye ayiqonda kancinci injongo yokuphila ixesha elide, ukujonga ukuphinda kwesifo kube yingxaki enkulu yezonyango, kwaye ukuba uvavanyo lwe-MRD lunokudlala indima ebalulekileyo na kulo lufanele luhlolwe kwiimvavanyo zonyango ezongezelelweyo.